PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550579
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550579
Global chemiluminescence immunoassay market is estimated to be valued at USD 13.11 Bn in 2024 and is expected to reach USD 20.50 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | US$ 13.11 Bn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 6.60% | 2031 Value Projection: | US$ 20.50 Bn |
Chemiluminescence immunoassay is a biochemical test technique that is used for detecting and quantifying antigens, antibodies, and other proteins in a liquid sample. It combines the specificity of antigen-antibody reaction with a luminescent reaction to produce a photon signal that can be measured with a luminometer. The technique has gained popularity in clinical diagnostics, owing to its high sensitivity and reliability. It allows measurement of various biomarkers at picogram or femtogram concentrations directly in serum or plasma without requiring lengthy incubations or wash steps. Global chemiluminescence immunoassay market growth is driven by growing need for advanced immunoassay techniques in clinical diagnostics. Its wide applications in disease screening, therapeutic drug monitoring, and endocrinology can drive the market growth.
Global chemiluminescence immunoassay market growth is driven by rising geriatric population and growing prevalence of chronic and infectious diseases. According to WHO, chronic diseases are estimated to account for over 60% of all deaths globally each year. Moreover, increasing investments by hospitals and diagnostic centers to upgrade their medical facilities with advanced diagnostic platforms can drive the market growth. However, stringent regulatory guidelines for new product approvals and the need for specialized equipment and technicians can hamper the market growth. The market players have opportunities to develop fully automated, compact chemiluminescence immunoassay systems with higher throughput and enhanced point-of-care capabilities..
This report provides in-depth analysis of the global chemiluminescence immunoassay market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chemiluminescence immunoassay market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Roche Diagnostics, Abbott, Siemens Healthcare, Beckman Coulter, Ortho-Clinical Diagnostics, and BioMerieux
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global chemiluminescence immunoassay market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chemiluminescence immunoassay market
Detailed Segmentation-